Press releases and official statements
![](/sites/default/files/styles/download_preview/public/2024-06/press_release_networktrialaward_2024.png)
SAKK Network Trial Award Press release
![](/sites/default/files/styles/download_preview/public/2024-06/press_release_awards_2024.png)
SAKK Awards 2024 Press release
![Sinkende Therapiekosten und reduzierte Nebenwirkungen](/sites/default/files/styles/download_preview/public/2024-06/mm_240603_sinkende_therapiekosten.png)
Sinkende Therapiekosten und reduzierte Nebenwirkungen
Press release, June 6, 2024. Available languages:
![](/sites/default/files/styles/download_preview/public/2024-05/press_release_new_ceo_05_24.png)
Vincent Gruntz is to be the new CEO of SAKK
Press release, May 31, 2024. Available languages:
![](/sites/default/files/styles/download_preview/public/2022-05/preview_mm_vorstand.jpg)
National Councilor Marianne Binder-Keller and Dr. Christian Rathgeb elected to the SAKK Board
Press release, May 5, 2022. Available languages:
![](/sites/default/files/styles/download_preview/public/2022-02/preview_medienmitteilung_neuer_ceo.jpg)
Hans Rudolf Keller is the new CEO of SAKK
Press release, January 27, 2022. Available languages:
![](/sites/default/files/styles/download_preview/public/2022-01/preview_mm_patientenrat.jpg)
Medienmitteilung des Patientenrats der SAKK: NEIN zum Tier- und Menschenversuchsverbot
January 17, 2022. Available languages:
![](/sites/default/files/styles/download_preview/public/2021-06/preview_pr_oasmia.jpg)
Oasmia Pharmaceutical AB: First Patient enrolled in the SAKK Investigator-Initiated Phase 1b trial of Docetaxel Micellar in Advanced Prostate Cancer
Press release, June 10, 2021. Available languages:
![](/sites/default/files/styles/download_preview/public/2021-01/preview_interview_von_moos_oncomag_4_2020.jpg)
Patienten, die in Studien behandelt werden, haben ein besseres Outcome
In Gespräch mit Prof. Dr. med. Roger von Moos.
Download Deutsch.
OncoMag 4/2020.
Download Deutsch.
OncoMag 4/2020.
![](/sites/default/files/styles/download_preview/public/2020-12/preview_faq.jpg)
FAQs on SAKK's financial situation and its restructuring plan
![](/sites/default/files/styles/download_preview/public/2020-06/prevew_stellungsnahme_0.jpg)
Joint statement on the popular initiative "Yes to the ban on animal and human experiments”
June 4, 2020. Available languages:
![](/sites/default/files/styles/download_preview/public/2020-03/preview_aron_goldhirsch.jpg)
Professor Aron Goldhirsch (1946-2020): An exeptional Oncologist, Scientist and Teacher
March 04, 2020. Available languages:
![](/sites/default/files/styles/download_preview/public/2020-03/preview_establishing.jpg)
Establishing a SAKK Working Group for Cellular Therapies
Press release, December 12, 2019. Available languages:
![](/sites/default/files/styles/download_preview/public/2019-12/preview_pm_celgen_life_grant.jpg)
SAKK / Celgene «Life Grant» 2019
Press release, November 22, 2019. Available languages:
![](/sites/default/files/styles/download_preview/public/2019-12/preview_nzzas_kinderspitaele_pharma.jpg)
Kinderspitäler beklagen schwindende Pharmagelder
NZZ am Sonntag, November 17, 2019. Available languages:
![](/sites/default/files/styles/download_preview/public/2019-11/preview.jpg)
Pascal Coullery: Der Forschungsbegriff des Krankenversicherungsgesetzes
Gutachten über die Rechtmässigkeit abgelehnter Kostenübernahme durch die Krankenkassen.
Download Deutsch
Download Deutsch
![](/sites/default/files/styles/download_preview/public/2019-10/preview_press_release_pharmamar.jpg)
Lurbinectedin data in Progressive Malignant Pleural Mesothelioma presented at ESMO (SAKK 17/16)
Download english
![](/sites/default/files/styles/download_preview/public/2019-08/preview_hem_pioneer_pr.jpg)
SAKK / Celgene “HEM Pioneer Grant” 2019 Press Release
![](/sites/default/files/styles/download_preview/public/2019-08/preview_nzzas.jpg)
Unispitäle steigen in Krebstherapie ein
NZZ am Sonntag, July 28, 2019. Available languages:
![](/sites/default/files/styles/download_preview/public/2019-05/mediaplanet.jpg)
Krebs noch zielgerichteter behandeln
Article from April 10, 2019 in Planet Gesundheit
![](/sites/default/files/styles/download_preview/public/2019-01/190110_innomedica_preview.png)
InnoMedica Holding AG: First cancer patient treated with liposomal doxorubicin
Press release, 10 January 2019. Available languages:
![](/sites/default/files/styles/download_preview/public/2019-01/190108_preview_mm.png)
Extension of the research network to regional hospitals
Press release, 8 January 2019. Available languages:
![](/sites/default/files/styles/download_preview/public/2018-12/181218_preview_medienmitteilung_pharmamar_0.png)
SAKK 17/16 Phase II trial of lurbinectedin in progressive mesothelioma
Press release, 17 December 2018. Available languages:
![](/sites/default/files/styles/download_preview/public/2018-11/181129_bund_bessergunstige_preview.png)
Besser, günstiger, aber unrentabel
Der Bund, 23 November 2018. Available languages:
![](/sites/default/files/styles/download_preview/public/2018-11/_mg_2339.jpg)
The 2018 GIST award goes to Dr. med. Michael Montemurro, CHUV, Lausanne and SAKK
Press release, 22 November 2018. Available languages:
![](/sites/default/files/styles/download_preview/public/2018-08/nzz.jpg)
Gute Medikamente, böse Pharma
NZZ article, 18 July 2018. Available languages:
![](/sites/default/files/styles/download_preview/public/2018-08/medien.jpg)
InnoMedica bringt erstes Krebsmedikament mit der SAKK in die Schweizer Spitäler
Press release, 2 March 2017. Available languages:
![](/sites/default/files/styles/download_preview/public/2018-08/medien.jpg)
Further strengthening the network of cancer centres in Switzerland
Press release, 1 July 2016. Available languages:
![](/sites/default/files/styles/download_preview/public/2018-08/medien.jpg)
Swiss cancer research network establishes patient representative board
Press release, 3 December 2015. Available languages:
![](/sites/default/files/styles/download_preview/public/2018-08/scto.jpg)
Patientenorientierte klinische Forschung in der Schweiz: 5 prioritäre Handlungsfelder
Fields of action. Available languages: